Head to Head Contrast: Stoke Therapeutics (STOK) vs. Its Peers

Stoke Therapeutics (NASDAQ:STOK) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Stoke Therapeutics to similar companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Stoke Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-862.07%	-66.76%	-58.10%
Stoke Therapeutics Competitors	-9,051.23%	-201.20%	-30.64%

Analyst Recommendations

This is a summary of recent ratings for Stoke Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1	0	10	0	2.82
Stoke Therapeutics Competitors	9792	15073	45355	1574	2.54

Stoke Therapeutics presently has a consensus price target of $44.17, suggesting a potential upside of 65.00%. As a group, “Biotechnology” companies have a potential upside of 96.40%. Given Stoke Therapeutics’ competitors higher possible upside, analysts plainly believe Stoke Therapeutics has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

47.9% of shares of all “Biotechnology” companies are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Stoke Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Stoke Therapeutics’ competitors have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Valuation and Earnings

This table compares Stoke Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Stoke Therapeutics	$28.21 million	-$6.89 million	-7.10
Stoke Therapeutics Competitors	$727.61 million	$12.25 million	-10.24

Stoke Therapeutics’ competitors have higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Stoke Therapeutics competitors beat Stoke Therapeutics on 7 of the 13 factors compared.

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.